Lipopolysaccharide in Systemic Circulation Induces Activation of Inflammatory Response and Oxidative Stress in Cardiorenal Syndrome Type 1

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2019 Apr 22

PMID 31006081

Citations 8

Authors

Grazia Maria Virzi

Andrea Breglia

Chiara Castellani

Ghada Ankawi

Chiara Bolin

Massimo De Cal

Vito Cianci

Annalisa Angelini

Giorgio Vescovo

Claudio Ronco

Affiliations

Soon will be listed here.

Abstract

Background: Cardiorenal syndrome type 1 (CRS type 1) is characterized by a rapid worsening of cardiac function leading to acute kidney injury. In this study, we evaluate the role of lipopolysaccharide (LPS) and various inflammatory markers in the developing acute kidney injury (AKI) in acute heart failure (AHF) patients.

Methods: We enrolled 31 AHF patients and 20 CRS type 1 (the cause of AKI was presumed to be related to cardiac dysfunction) and 17 healthy volunteers without AHF, AKI or CKD, as control group (CTR). We assessed levels of LPS, proinflammatory cytokines (TNF-α, IL-6, IL-18), and oxidative stress marker (myeloperoxidase, MPO).

Results: We observed a significant increase in LPS, TNF-α, IL-6, IL-18 and MPO levels in CRS type 1 and AHF group compared to CTR. LPS levels resulted significantly higher in CRS type 1 patients compared with AHF (118.2 pg/mL, IQR 77.8-217.6 versus 13.5 pg/mL, IQR 12.0-17.0, p = 0.008). We found a cytokines and oxidative stress dysregulation in CRS type 1 patients compared with AHF. Furthermore, we observed a strong positive significant correlation between LPS levels and IL-6 (Spearman's rho = 0.79, p < 0.001), and IL-18 (Spearman's rho = 0.77, p < 0.001) and MPO (Spearman's rho = 0.80, p < 0.001), all confirm by simple linear regression analysis.

Conclusion: CRS type 1 patients presented an increased level of LPS, pro-inflammatory cytokines, and MPO. Furthermore, there is a direct correlation between LPS and pro-inflammatory cytokines and stress oxidative marker. LPS may play a role in the pathophysiology of CRS type 1 inducing inflammation, oxidative stress and finally kidney damage.

Citing Articles

The Role of Oxidative Stress as a Mechanism in the Pathogenesis of Acute Heart Failure in Acute Kidney Injury.

Tasic D, Dimitrijevic Z Diagnostics (Basel). 2024; 14(18).

PMID: 39335773 PMC: 11431490. DOI: 10.3390/diagnostics14182094.

Endogenous Dysregulation of Thromboinflammatory Biomarkers in End-Stage Renal Disease, and Their Amplification by Heart Failure.

Robbin V, Bansal V, Siddiqui F, Allen M, Hoppensteadt-Moorman D, Kantarcioglu B Clin Appl Thromb Hemost. 2024; 30:10760296241263858.

PMID: 39140866 PMC: 11325466. DOI: 10.1177/10760296241263858.

Gut microbiota metabolites, redox status, and the related regulatory effects of probiotics.

Zhao J, Zhao F, Yuan J, Liu H, Wang Y Heliyon. 2023; 9(11):e21431.

PMID: 38027795 PMC: 10643359. DOI: 10.1016/j.heliyon.2023.e21431.

Perfusate Neutrophil Gelatinase-Associated Lipocalin, Kidney Injury Molecular-1, Liver-Type Fatty Acid Binding Protein, and Interleukin-18 as Potential Biomarkers to Predict Delayed Graft Function and Long-Term Prognosis in Kidney Transplant....

Sun Z, Gao Z, Li X, Zheng X, Wang W, Qiao P Med Sci Monit. 2023; 29:e938758.

PMID: 36869580 PMC: 9993774. DOI: 10.12659/MSM.938758.

Endotoxin in Sepsis: Methods for LPS Detection and the Use of Omics Techniques.

Virzi G, Mattiotti M, De Cal M, Ronco C, Zanella M, De Rosa S Diagnostics (Basel). 2023; 13(1).

PMID: 36611371 PMC: 9818564. DOI: 10.3390/diagnostics13010079.

References

Niebauer J, Volk H, Kemp M, Dominguez M, Schumann R, Rauchhaus M . Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999; 353(9167):1838-42. DOI: 10.1016/S0140-6736(98)09286-1. View

Bannerman D, Goldblum S . Direct effects of endotoxin on the endothelium: barrier function and injury. Lab Invest. 1999; 79(10):1181-99. View

Hassoun H, Kone B, MERCER D, Moody F, Weisbrodt N, Moore F . Post-injury multiple organ failure: the role of the gut. Shock. 2001; 15(1):1-10. DOI: 10.1097/00024382-200115010-00001. View

Guha M, Mackman N . LPS induction of gene expression in human monocytes. Cell Signal. 2001; 13(2):85-94. DOI: 10.1016/s0898-6568(00)00149-2. View

Conraads V, Jorens P, De Clerck L, van Saene H, Ieven M, Bosmans J . Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004; 6(4):483-91. DOI: 10.1016/j.ejheart.2003.12.004. View

Zager R, Johnson A, Lund S, Hanson S, Abrass C . Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006; 290(6):F1453-62. DOI: 10.1152/ajprenal.00485.2005. View

Goncalves S, Pecoits-Filho R, Perreto S, Barberato S, Stinghen A, Lima E . Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant. 2006; 21(10):2788-94. DOI: 10.1093/ndt/gfl273. View

Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D . Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11(2):R31. PMC: 2206446. DOI: 10.1186/cc5713. View

Charalambous B, Stephens R, Feavers I, Montgomery H . Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock. 2007; 28(1):15-23. DOI: 10.1097/shk.0b013e318033ebc5. View

10.

Celis R, Torre-Martinez G, Torre-Amione G . Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?. Curr Opin Cardiol. 2008; 23(3):254-60. DOI: 10.1097/HCO.0b013e3282fbfbc7. View

11.

Ronco C, Haapio M, House A, Anavekar N, Bellomo R . Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52(19):1527-39. DOI: 10.1016/j.jacc.2008.07.051. View

12.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

13.

von Haehling S, Schefold J, Lainscak M, Doehner W, Anker S . Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin. 2009; 5(4):549-60. DOI: 10.1016/j.hfc.2009.04.001. View

14.

Colombo P, Ganda A, Lin J, Onat D, Harxhi A, Iyasere J . Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2011; 17(2):177-90. PMC: 3876739. DOI: 10.1007/s10741-011-9261-3. View

15.

Rosner M, Ronco C, Okusa M . The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. Semin Nephrol. 2012; 32(1):70-8. DOI: 10.1016/j.semnephrol.2011.11.010. View

16.

Virzi G, Torregrossa R, Cruz D, Chionh C, De Cal M, Soni S . Cardiorenal Syndrome Type 1 May Be Immunologically Mediated: A Pilot Evaluation of Monocyte Apoptosis. Cardiorenal Med. 2012; 2(1):33-42. PMC: 3318942. DOI: 10.1159/000335499. View

17.

McMurray J, Adamopoulos S, Anker S, Auricchio A, Bohm M, Dickstein K . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the.... Eur Heart J. 2012; 33(14):1787-847. DOI: 10.1093/eurheartj/ehs104. View

18.

Ronco C, Cicoira M, McCullough P . Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol. 2012; 60(12):1031-42. DOI: 10.1016/j.jacc.2012.01.077. View

19.

Virzi G, Day S, De Cal M, Vescovo G, Ronco C . Heart-kidney crosstalk and role of humoral signaling in critical illness. Crit Care. 2014; 18(1):201. PMC: 4059499. DOI: 10.1186/cc13177. View

20.

Ronco C, Di Lullo L . Cardiorenal syndrome. Heart Fail Clin. 2014; 10(2):251-80. DOI: 10.1016/j.hfc.2013.12.003. View